FGP
HRMY icon

Freestone Grove Partners’s Harmony Biosciences HRMY Stock Holding History

Freestone Grove Partners’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Sell
30,813
-9,791
-24% -$309K 0.01% 516
2026
Q1 		$1.14M Buy
+40,604
New +$1.33M 0.01% 448
2025
Q4 		– Sell
-25,921
Closed -$714K – 817
2025
Q3 		$714K Buy
+25,921
New +$893K 0.01% 486

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Freestone Grove Partners's HRMY Position: Q2 2026 in Review

Freestone Grove Partners reduced its Harmony Biosciences (HRMY) stake by 24% in Q2 2026, selling an estimated $309K and leaving 30,813 shares worth $1.12M. The position accounts for 0.01% of the portfolio, ranked #516.

Freestone Grove Partners first reported a position in HRMY in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.14M in Q1 2026. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Freestone Grove Partners held 30,813 shares of Harmony Biosciences worth $1.12M as of Q2 2026.
  • Freestone Grove Partners sold 9,791 Harmony Biosciences shares in Q2 2026, an estimated $309K.
  • Harmony Biosciences made up 0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #516 holding.
  • Freestone Grove Partners first reported a position in Harmony Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Freestone Grove Partners's Harmony Biosciences position peaked at $1.14M in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.